The Expression Levels of Serum IGFBP-3 and Angptl-2 in Patients with Different Molecular Types of Breast Cancer and Their Correlation with Bone Metastasis and Prognosis
Objective:To analyze the expression levels of serum insulin-like growth factor-binding protein 3(IGFBP-3)and angiopoietin 2(Angptl-2)and their correlation with bone metastasis and prognosis in patients with different molecularly typed breast cancer.Methods:One hundred and twenty-eight patients with breast cancer bone metastases admitted to Zhongda Hospital Southeast University(Jiangbei)from March 2018 to March 2021 were selected for the study,including 50 cases of Luminal A,42 cases of Luminal B(HER-2 negative),42 cases of HER-2 overexpression,16 cases of triple-negative breast cancer(TNBC),20 cases of TNBC,and analyzed the four molecular subtypes of breast cancer The clinicopathological characteristics of the four molecular subtypes of breast cancer were analyzed,and the expression levels of serum IGFBP-3 and Angptl-2 were detected by enzyme-linked immunosorbent assay;the prognosis of the two groups of patients was recorded after 24 months of follow-up,and a multifactorial logistic model was used to analyze the independent risk factors that affect the prognosis of patients with bone metastases of the four molecular subtypes of breast cancer and the correlation between serum IGFBP-3 and Angptl-2 and the prognosis of patients with bone metastases of different molecular subtypes of breast cancer.prognosis of patients with bone metastases from different molecular typing of breast cancer.Results:Luminal A type,Luminal B type,HER-2 overexpression type,and TNBC type TNM staging and lymph node metastasis were compared,and the difference was statistically significant(P＜0.05).Compared with patients with breast cancer bone metastasis of Luminal A type,Luminal B type,and TNBC type,patients with breast cancer bone metastasis of HER-2 overexpression type had lower serum IGFBP-3 expression levels and higher Angptl-2 expression levels(P＜0.05).Luminal A type,Luminal B type,HER-2 overexpression type,and TNBC type The mortality rates of patients with breast cancer bone metastases were 13.46％,38.46％,23.08％,and 25.00％,respectively.Multifactorial Logistic results showed that TNM stage,lymph node metastasis,serum IGFBP-3,and Angptl-2 were all independent risk factors affecting the prognosis of patients with bone metastasis from different molecular staging of breast cancer(P＜0.05).Abnormally high expression of serum IGFBP-3 suggested poor prognosis in patients with bone metastases of the four molecular staging breast cancers,while the expression level of Angptl-2 was positively correlated with the prognosis of the four molecular staging breast cancers(P＜0.05).For the prognostic prediction of patients with bone metastasis of different molecular typing breast cancer,serum IGFBP-3,Angptl-2,and IGFBP-3+Angptl-2 all showed AUC＞0.75.Conclusion:Serum IGFBP-3 and Angptl-2 can be used as potential biomarkers for patients with HER-2 overexpression of breast cancer bone metastases;meanwhile,they can also be used to predict the prognosis of patients with breast cancer bone metastases of different molecular staging based on the expression levels of serum IGFBP-3 and Angptl-2.
Breast cancerDifferent molecular typingIGFBP-3Angptl-2Bone metastasisPrognosis
NETL
NSTL
万方数据
